On
Non verificato

Oncoinvent

Di cosa scriviamo

FarmaceuticaIndustriaMedicina nucleareOncologiaSalute
01/11/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Medicina nucleare
Farmaceutica
Oncoinvent Announces Publication of 18-Month Safety and Efficacy Data from the Phase 1/2a Study of Radspherin® in Colorectal Cancer
1.00
10/10/2024
Industria
Medicina nucleare
Farmaceutica
Medicina - Varie
Oncologia
Sanità
Salute
Igiene alimentare
Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0